Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Hengrui Presents 64 Oncology Studies at ESMO Congress 2026

By Public Technologies
  • Hengrui Pharma presented a company-record 64 oncology studies at the ESMO Congress 2026 in Madrid, covering 21 innovative drugs.
  • The research included nine marketed products and 12 investigational candidates across more than ten cancer areas.
  • As of June 2026, its oncology portfolio included 14 independently developed medicines marketed in China, with around 50 innovative assets in clinical development.
  • Innovative oncology medicines generated 81.02% of total innovative medicine sales revenue in 2025, underscoring the business's commercial importance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN83019) on October 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.